Current treatment options for HER2-positive breast cancer patients with brain metastases.
Brain metastases
HER2-positive breast cancer
Lapatinib
Neratinib
Trastuzumab
Trastuzumab deruxtecan
Trastuzumab-emtansine
Tucatinib
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
16
04
2020
revised:
03
03
2021
accepted:
26
03
2021
pubmed:
17
4
2021
medline:
2
6
2021
entrez:
16
4
2021
Statut:
ppublish
Résumé
Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development of effective systemic therapy to prevent and treat BMs from HER2 + BC represents an unmet clinical need. Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice. More recently, novel agents such as neratinib, tucatinib and trastuzumab deruxtecan have been developed, with interesting activity against BMs. Further research is needed to better elucidate the best sequence of these agents and their combination with local treatment.
Identifiants
pubmed: 33862249
pii: S1040-8428(21)00117-7
doi: 10.1016/j.critrevonc.2021.103329
pii:
doi:
Substances chimiques
Oxazoles
0
Pyridines
0
Quinazolines
0
tucatinib
234248D0HH
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103329Informations de copyright
Copyright © 2021. Published by Elsevier B.V.